H.R. 10150, Pharmaceutical Market Exclusivity Expansion. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
H.R. 10150 · Mixed
What it does
This bill amends federal drug law to grant botanical drugs (plant-derived medicines approved by the FDA) a 12-year period of market exclusivity, during which generic or follow-on versions cannot be approved. The bill aims to incentivize pharmaceutical companies to invest in developing complex plant-based treatments for chronic and age-related diseases by protecting their market position after approval, similar to exclusivity periods already granted to other drug categories.
The analysis names pharmaceutical companies developing botanical drugs — and 2 more groups — among the beneficiaries.
The trade-off
The 12-year exclusivity period applies to ALL botanical drugs approved after enactment, regardless of whether they represent genuine innovation or minor reformulations of existing products, potentially extending monopoly pricing on incremental improvements.
Transparency scores 85%, with a medium warning level and no provisions unrelated to the bill's subject.
Who is behind it
Filed by Lauren Boebert. Cosponsored by Derrick Van Orden.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.